Abstract
Idiopathic pulmonary fibrosis (IPF) is a disease with limited therapeutic options. Corticosteroids and immunouppressive agents have been the mainstays of treatment, primarily due to their anti-inflammatory properties. However, they have demonstrated minimal efficacy and significant toxicity. Recent efforts have sought to target other aspects of the pathophysiology of this condition. Several investigators have hypothesized that imbalances of coagulation and fibrinolysis play a role in the pathophysiology of IPF. Thrombin has been identified as a possible trigger of fibroblast proliferation in IPF, suggesting a role for thrombin inhibition in modifying the course of disease. Furthermore, anticoagulation may have a role in preventing thrombotic complications in IPF patients with secondary pulmonary hypertension. This review will discuss the potential role for anticoagulation in the treatment of IPF. One randomised control trial has demonstrated a significant survival benefit associated with anticoagulation of IPF patients. We will review the evidence supporting this treatment strategy, as well as its possible mechanisms of action.
Keywords: Idiopathic pulmonary fibrosis, anticoagulation, thrombin
Current Respiratory Medicine Reviews
Title: The Role of Anticoagulation in IPF
Volume: 3 Issue: 3
Author(s): Geetika Verma, Matthew Binnie and Charles K.N. Chan
Affiliation:
Keywords: Idiopathic pulmonary fibrosis, anticoagulation, thrombin
Abstract: Idiopathic pulmonary fibrosis (IPF) is a disease with limited therapeutic options. Corticosteroids and immunouppressive agents have been the mainstays of treatment, primarily due to their anti-inflammatory properties. However, they have demonstrated minimal efficacy and significant toxicity. Recent efforts have sought to target other aspects of the pathophysiology of this condition. Several investigators have hypothesized that imbalances of coagulation and fibrinolysis play a role in the pathophysiology of IPF. Thrombin has been identified as a possible trigger of fibroblast proliferation in IPF, suggesting a role for thrombin inhibition in modifying the course of disease. Furthermore, anticoagulation may have a role in preventing thrombotic complications in IPF patients with secondary pulmonary hypertension. This review will discuss the potential role for anticoagulation in the treatment of IPF. One randomised control trial has demonstrated a significant survival benefit associated with anticoagulation of IPF patients. We will review the evidence supporting this treatment strategy, as well as its possible mechanisms of action.
Export Options
About this article
Cite this article as:
Geetika Verma , Matthew Binnie and Charles K.N. Chan , The Role of Anticoagulation in IPF, Current Respiratory Medicine Reviews 2007; 3 (3) . https://dx.doi.org/10.2174/157339807781387526
DOI https://dx.doi.org/10.2174/157339807781387526 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Burden of Cardiovascular Disease Risk Factors in the Middle East: A Systematic Review and Meta-Analysis Focusing on Primary Prevention
Current Vascular Pharmacology Diltiazem Analogues: The Last Ten Years on Structure Activity Relationships
Current Medicinal Chemistry Cognitive Impairment and Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives
Current Medicinal Chemistry Role of the Transforming-Growth-Factor-β1 Gene in Late-Onset Alzheimer’s Disease: Implications for the Treatment
Current Genomics Development and Characterization of Nasal Delivery of Selegiline Hydrochloride Loaded Nanolipid Carriers for the Management of Parkinson’s Disease
Central Nervous System Agents in Medicinal Chemistry Overview of Covid-19 Regarding the Cardiovascular Situation in the Light of Current Reports
Cardiovascular & Hematological Disorders-Drug Targets Childhood Systemic Lupus Erythematosus: New and Old Treatments
Current Pediatric Reviews Aligning Animal Models of Clinical Germinal Matrix Hemorrhage, From Basic Correlation to Therapeutic Approach
Current Drug Targets Collateral Circulation in Chronic Total Occlusions – an interventional perspective
Current Cardiology Reviews The Biology and Therapeutic Potential of the DDAH/ADMA Pathway
Current Pharmaceutical Design Prevention of Ischemic Stroke: Overview of Traditional Risk Factors
Current Drug Targets Interactions of Endothelin and Insulin: Expanding Parameters of Insulin Resistance
Current Diabetes Reviews Pathogenesis and Therapeutics of Interstitial Lung Disease in Systemic Sclerosis
Current Rheumatology Reviews Regulation of Blood Flow by Prostaglandins
Current Vascular Pharmacology Conference Report: 184th American Association for the Advancement of Science Annual Meeting, Austin TX, USA Feb. 15-19, 2018
CNS & Neurological Disorders - Drug Targets Assessment and Clinical Relevance of Non-Fasting and Postprandial Triglycerides: An Expert Panel Statement
Current Vascular Pharmacology The Effect of Ethyl Acetate Extract of Pomelo Mix on Systemic Exposure of Verapamil in Rabbits
Drug Metabolism Letters Targeting the Multifaceted HuR Protein, Benefits and Caveats
Current Drug Targets Creatine and the Liver: Metabolism and Possible Interactions
Mini-Reviews in Medicinal Chemistry